azlocillin | 67843-92-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: azlocillin
• 英文别名: (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 67843-92-9
• 化学式: C₂₀H₂₃N₅O₆S
• 分子量: 461.499
• InChiKey: JTWOMNBEOCYFNV-XQERAMJGSA-N

物化性质

• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  173
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• 6-Alpha-hydroxymethylpenicillanic acid sulfone as a beta-lactamase inhibitor
  申请人：PFIZER INC.

  公开号：EP0083977A1

  公开（公告）日：1983-07-20

  6-alpha-hydroxymethylpenicillanic acid sulfone as a useful enhancer of the effectiveness of several beta-lactam antibiotics against many beta-lactamase producing bacteria, and 6-alpha-hydroxymethylpenicillanic acid sulfone benzyl ester as a useful intermediate leading to said agent which enhance the effectiveness of beta-lactam antibiotics.

  6-α-羟甲基青霉烷酸砜作为一种有用的增强剂，可增强几种β-内酰胺类抗生素对许多产β-内酰胺酶细菌的效力；6-α-羟甲基青霉烷酸砜苄酯作为一种有用的中间体，可产生上述增强β-内酰胺类抗生素效力的制剂。
• Treatment of acute myeloid leukemia
  申请人：Ottawa Hospital Research Institute

  公开号：US11339448B2

  公开（公告）日：2022-05-24

  Herein are described methods of treating a human subject having acute myeloid leukemia (AML) that is refractory to induction therapy, wherein an MDM2 inhibitor is administered before or concurrently with chemotherapy, which may comprise induction therapy. Refractory AML may be predicted based on decreased expression of MTF2 in cells from a hematological sample obtained from the subject. Also provided are methods of predicting and treating AML responsive to MDM2/HDM2 inhibitors, based on MTF2 expression. One set of additional biomarkers useful in the predictions comprise one or more of H3K27me3, CD84, CD92, MDM2, NPM1, PRICKLE1, SET, ABCB6, POLQ, POLK, POLH, ARTIMIS, MCM6, CD327, CD90 and PARP1. Another set of additional biomarkers useful in the predictions include at least one of H3K27me3, MDM2, NPM1, SET, CD84 and PRICKLE1. Methods of selecting a patient for treatment with an MDM2 inhibitor before or concurrently with chemotherapy are also provided, along with kits and uses.

  本文描述了治疗对诱导疗法难治的急性髓性白血病（AML）人类受试者的方法，其中在化疗之前或与化疗同时施用MDM2抑制剂，化疗可包括诱导疗法。难治性 AML 可根据从受试者处获得的血液样本细胞中 MTF2 表达量的降低来预测。还提供了基于 MTF2 表达预测和治疗对 MDM2/HDM2 抑制剂有反应的 AML 的方法。在预测中有用的一组附加生物标记物包括H3K27me3、CD84、CD92、MDM2、NPM1、PRICKLE1、SET、ABCB6、POLQ、POLK、POLH、ARTIMIS、MCM6、CD327、CD90和PARP1中的一种或多种。在预测中有用的另一组附加生物标记物包括 H3K27me3、MDM2、NPM1、SET、CD84 和 PRICKLE1 中的至少一种。此外，还提供了在化疗前或与化疗同时使用 MDM2 抑制剂治疗患者的选择方法，以及试剂盒和用途。
• Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions
  申请人：PFIZER INC.

  公开号：EP0008917B1

  公开（公告）日：1982-11-24
• Penicillanic acid dioxide prodrug
  申请人：PFIZER INC.

  公开号：EP0095341B1

  公开（公告）日：1986-02-26
• TREATMENT OF ACUTE MYELOID LEUKEMIA
  申请人：Ottawa Hospital Research Institute

  公开号：US20200040403A1

  公开（公告）日：2020-02-06

  Herein are described methods of treating a human subject having acute myeloid leukemia (AML) that is refractory to induction therapy, wherein an MDM2 inhibitor is administered before or concurrently with chemotherapy, which may comprise induction therapy. Refractory AML may be predicted based on decreased expression of MTF2 in cells from a hematological sample obtained from the subject. Also provided are methods of predicting and treating AML responsive to MDM2/HDM2 inhibitors, based on MTF2 expression. One set of additional biomarkers useful in the predictions comprise one or more of H3K27me3, CD84, CD92, MDM2, NPM1, PRICKLE1, SET, ABCB6, POLQ, POLK, POLH, ARTIMIS, MCM6, CD327, CD90 and PARP1. Another set of additional biomarkers useful in the predictions include at least one of H3K27me3, MDM2, NPM1, SET, CD84 and PRICKLE1. Methods of selecting a patient for treatment with an MDM2 inhibitor before or concurrently with chemotherapy are also provided, along with kits and uses.